Edwards Lifesciences Corp(EW) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 5:55 PM ET (Korea 10/29 06:55)
Full metrics table
| Index | S&P 500 | P/E | 54.46 | EPS (ttm) | 1.69 | Insider Own | 1.22% | Shs Outstand | 576.6M | Perf Week | 3.82% |
| Market Cap | 52.90B | Forward P/E | 27.1 | EPS next Y | 12.93% | Insider Trans | -1.89% | Shs Float | 569.4M | Perf Month | 4.2% |
| Enterprise Value | 49.46B | PEG | 1.92 | EPS next Q | 0.74 | Inst Own | 93.52% | Short Float | 1.64% | Perf Quarter | 5.59% |
| Income | 0.98B | P/S | 8.12 | EPS this Y | 17.13% | Inst Trans | 1.15% | Short Ratio | 2.76 | Perf Half Y | 13% |
| Sales | 6.51B | P/B | 4.98 | EPS next 5Y | 14.15% | ROA | 7.16% | Short Interest | 9.33M | Perf YTD | 7.66% |
| Book/sh | 18.41 | P/C | 12.43 | EPS past 3/5Y | -9.46% 6.79% | ROE | 9.26% | 52W High | -4.68% ($96.29) | Perf Year | 11.67% |
| Cash/sh | 7.38 | P/FCF | 36.9 | Sales past 3/5Y | 4.08% 6.7% | ROIC | 8.67% | 52W Low | 22.93% ($74.66) | Perf 3Y | 48.73% |
| Dividend Est. | - | EV/EBITDA | 24.44 | EPS Y/Y TTM | 15.09% | Gross Margin | 78.28% | Volatility(W/M) | 2.18% 2.36% | Perf 5Y | -21.23% |
| Dividend TTM | - | EV/Sales | 7.59 | Sales Y/Y TTM | 14.55% | Oper. Margin | 28.53% | ATR (14) | 2.01 | Perf 10Y | 186.34% |
| Dividend Ex-Date | - | Quick Ratio | 3.77 | EPS Q/Q | -27.06% | Profit Margin | 15.05% | RSI (14) | 63.61 | Recom | 1.62 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.52 | Sales Q/Q | 13.63% | SMA20 | 4.99% ($87.42) | Beta | 0.86 | Target Price | $102.42 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/11/4 | SMA50 | 4.23% ($88.06) | Rel Volume | 0.68 | Prev Close | $90.82 |
| Employees | 16000 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | 4.97% 2.4% | SMA200 | 7.56% ($85.33) | Avg Volume(3M) | 3.38M | Price | $91.78 |
| IPO | 2000/3/27 | Option/Short | Yes/Yes | Trades | 21410 | Volume | 2,292,749 | Change | 1.06% |
A global leading medical device company specializing in heart valve disease treatment. Founded in the United States in 1958 by Miles Lowell Edwards and headquartered in Irvine, California, the company holds a leading position in the structural heart disease treatment device market, including transcatheter aortic valve replacement (TAVR).
Over the past 1 year, on the higher side
5% below its 1-year high.
Traded less than usual. That is 68% of its average volume.
Next earnings report: November 4
7 days to go.
EW makes money exceptionally well
Of every $100 in sales, $28.53 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +17.1% this year.
Tap to view numbers
However, it looks expensive
Counting its debt, for $100 of yearly operating cash you would pay $2,444. Peers typically go for $1,594. Compared with its own 4-year average, it is 56% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -21.2%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 93.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
IHI iShares U.S. Medical Devices ETF 0.05% 
AGNG Global X Aging Population ETF 0.03% 
GDOC Goldman Sachs Future Health Care Equity ETF 0.03% 
MDEV First Trust Indxx Medical Devices ETF 0.02% 
FMED Fidelity Disruptive Medicine ETF 0.02% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
EMLP First Trust North American Energy Infrastructure Fund 4.2B 
QCLN First Trust Nasdaq Clean Edge Green Energy Index Fund 488M 
PBW Invesco WilderHill Clean Energy ETF 298M 
SMOG VanEck Low Carbon Energy ETF 126M 
PBD Invesco Global Clean Energy ETF 100M It ranks #5 of 142 in the industry
Based on market cap of $53B.
BSX#4 Boston Scientific Corp $61B PER 17.2 
EW#5 Edwards Lifesciences Corp $53B PER 54.5 
GEHC#6 GE HealthCare Technologies Inc $34B PER 17.4 
DXCM#7 Dexcom Inc $30B PER 31.0 
PHG#8 Koninklijke Philips NV ADR $26B PER 20.1 
FAQ
What kind of company is EW?
EW belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of EW?
The market cap of EW is approximately $52.9B, ranking 307 within its sector.
What is the P/E ratio of EW?
EW has a P/E ratio of approximately 54.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for EW?
EW has recorded a 52-week high of $96.29 and a low of $74.66.
